BCL2 and neoplasm: We show that galacto‐conjugation of the BCL‐2 family inhibitor Navitoclax allows therapeutically relevant activity in subcutaneous tumour xenografts and orthotopic mouse models of chemotherapy‐induced senescence in the context of lung carcinoma.